Adjutor Group is an Australia-based healthcare consultancy focused on accelerating the development, registration, and commercialisation of innovative medicines and medical technologies across global markets. With a strong presence in Australia, New Zealand, and Hong Kong, and a trusted international partner network, Adjutor offers clients a single access point to key regions including Asia-Pacific, the EU/UK, and the Americas. Backed by over a decade of consulting experience, Adjutor combines expertise in regulatory, clinical, quality, and commercial domains. The team has supported the registration of hundreds of medicines and medical devices across all classes, helping clients navigate complex regulatory pathways while optimising timelines, cost, and risk. Adjutor provides end-to-end consultancy services covering product development strategy, clinical development, regulatory affairs, quality systems, training, sponsorship, and lifecycle management. Regulatory services include dossier preparation, submission management, agency interactions, and ongoing compliance support. Through local legal entities, Adjutor can also act as product sponsor in selected markets, facilitating efficient submissions and commercial supply. Clinical CRO services are delivered across multiple regions, spanning early strategy and feasibility to trial management and study reporting. Complementary quality and training services support the development of compliant systems aligned with global standards. Positioned at the intersection of clinical development, regulatory strategy, and market entry, Adjutor operates as a strategic partner to innovators, biotech companies, and investors, enabling seamless progression from concept to patient impact.
Visit Website
With a legacy dating back to 1935, we continue our ongoing mission to help a diverse variety of experts discover answers to some of life’s most important questions. Wherever people need answers that matter, you can find reliable technologies from Beckman Coulter Life Sciences.
A world leader in industrial microbiology testing, for more than 30 years, bioMérieux is present in 46 countries and serves more than 160 countries through a large network of distributors. bioMérieux provides contamination detection solutions (systems, reagents, software and services) to clients of the pharmaceutical industries. These solutions enable product quality control at all steps of the manufacturing process in order to protect patients’ and consumers’ safety. Our automated solutions and services answer laboratories’ challenges and help maximize their operational efficiency.
Bluecord is an electronic quality management system (eQMS) and manufacturing operations platform purpose-built for cell and gene therapy organizations. Bluecord helps academic medical centers, biotech companies, and GMP manufacturing facilities streamline quality, manufacturing, training, inventory, and regulatory workflows within a single validated cloud platform. Trusted by leading cell therapy programs globally, Bluecord supports compliant operations from early development through commercial manufacturing. The platform is designed specifically for the unique operational and regulatory needs of advanced therapies, enabling organizations to improve efficiency, maintain data integrity, and accelerate the delivery of life-saving treatments.
Doing good science is important. So is just doing good.
Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and led by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor for over 20 years. We consistently provide fellow scientists around the globe with best-in-class antibody products and services to fuel their quests for discovery. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide.
Helping researchers find new solutions is our main mission every day—but it’s not our only mission. We’re also dedicated to helping identify solutions to other problems facing our world. We believe that all businesses must be responsible and work in partnership with local communities, while seeking to minimize their environmental impact. That’s why we joined 1% for the Planet as its first life science member, and have committed to achieving net-zero emissions by 2029.
At CST, we believe in the power and promise of science to solve the challenges we face as a global community. We’re a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our customers, our communities, and our planet.
Charles River provides essential products and services to support pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide in accelerating research and drug development. As a leader in scientific innovation, we are deeply committed to pioneering alternative methods that drive discovery while reducing reliance on traditional models. By embracing cutting-edge technologies and forward-thinking approaches, we enhance preclinical and clinical research. Our dedicated employees focus on delivering precisely what our clients need to improve, innovate, and expedite the discovery, early-stage development, and safe manufacture of new therapies for patients—because every moment matters. Learn more at www.criver.com.
Cytiva is a global life sciences leader dedicated to helping customers discover and commercialize the next generation of therapeutics. With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
Eurofins Scientific through it's subsidiaries is the world leader in Food, Environment, Pharmaceutical and Cosmetic Products testing and in Agroscience CRO services. It is also one of the global independent market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and for supporting clinical studies.
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a well-recognized biotechnology company, GenScript has a team of approximately 6,165 employees and has served more than 200,000 customers across over 100 countries and regions.
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing. For more information on Kite, please visit www.kitepharma.com.
Ideagen is a global leader in governance, risk and compliance (GRC) software, helping more than 16,000 customers worldwide manage risk, ensure compliance and operate safely in highly regulated industries. Ideagen Quality Management (IQM, previously known as Q-Pulse) supports life sciences and healthcare organisations, including pathology, radiology, pharmaceutical and medical device providers, to streamline document control, training, audits, non-conformances and CAPA management within a single connected system. Built for organisations operating under strict regulatory frameworks such as ISO 13485, ISO 17025 and NATA accreditation, IQM gives quality and compliance teams real-time visibility over risk and performance, reducing manual administration and supporting continuous improvement and accreditation readiness. Across the ANZ region, Ideagen partners with cell and gene therapy providers, tissue banks and laboratories to help maintain the rigorous quality standards required to protect patient safety and product integrity. By bringing quality management processes into one platform, Ideagen helps organisations reduce risk, simplify compliance and free up time for the work that matters most: delivering safe, effective care.
Invetech is a health technology design, engineering and manufacturing company helping life sciences, diagnostics and cell and gene therapy innovators bring life-changing products to market. For 39 years, we have turned complex science into scalable reality, supporting clients from early feasibility through product development, regulatory-ready design, scale manufacturing and lifecycle support.
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to set industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of over 5,000 employees across 27 countries.
NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company’s research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.
Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the application of its proprietary StemSmart technology through a SAS program targeting fistulising Crohn’s disease—a severe and treatment-resistant form of the condition. Favourable outcomes will support the Company’s progression to a Phase 2 clinical trial to further evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn’s disease. This initiative aligns with NSB’s broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn’s disease, for whom current therapies remain inadequate.
Sartorius is a leading global partner of the biopharmaceutical industry dedicated to enabling cell and gene therapy developers to manufacture and commercialize their advanced therapy medicinal products (ATMPs). Over the last decade the company has expanded its legacy portfolio of single-use bioprocessing solutions through the acquisition of complementary advanced therapy consumables, services, and technologies—from plasmid engineering and manufacturing to cell culture media, reagents and monolithic chromatography. Sartorius’ advanced therapy solutions are designed to overcome current ATMP production challenges by enhancing productivity, improving process economics, and supporting safe and regulatory compliant manufacturing. Sartorius products are currently used in approved cell and gene therapies and actively support clinical pipelines worldwide. The company’s continued investment in innovative solutions demonstrates their commitment to advancing the field and making access to these life-saving treatments a reality.
Scientifix is a well-established Australian-owned life science product provider. Specialising in workflow solutions for cell biology including gene therapy stem cells, gene therapy MSCs, iPSCs and Exosomes, molecular biology, protein research and cryopreservation. Our tools for gene-editing reprogramming, stem-cell/iPSC culture, engineering, differentiation, and NGS analysis will remove technical hurdles to push experiments forward.
As a company of Scientists Helping Scientists, STEMCELL Technologies is committed to enabling cell and gene therapy research around the world with high-quality services and solutions. Whether you're editing CD34+ cells, differentiating PSCs, or expanding immune cells, we have the specialized cell isolation products, cell culture media, and reagents you need. Through our Services for Cell Therapy Program, we can help you qualify our products for use as ancillary materials. Learn more at www.STEMCELL.com.
Thermo Fisher Scientific is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer.